MBHB Partner Andrew Williams Quoted in BioPharma Article Entitled, “US biosimilars in 2016: Where we’re at following Zarxio’s breakthrough”

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Andrew Williams is quoted extensively in a January 6, 2016 online edition of BioPharma in an article entitled, “US biosimilars in 2016: Where we’re at following Zarxio’s breakthrough.” The coming year could see a spate of biosimilar approvals in the US following Sandoz’s success in 2015, according to an IP lawyer, but questions surrounding FDA’s requirements still remain. View the article

Search by Type
Menu
Menu